JP7759693B2 - モンテルカストおよびペプチドの新規接合体 - Google Patents

モンテルカストおよびペプチドの新規接合体

Info

Publication number
JP7759693B2
JP7759693B2 JP2021514112A JP2021514112A JP7759693B2 JP 7759693 B2 JP7759693 B2 JP 7759693B2 JP 2021514112 A JP2021514112 A JP 2021514112A JP 2021514112 A JP2021514112 A JP 2021514112A JP 7759693 B2 JP7759693 B2 JP 7759693B2
Authority
JP
Japan
Prior art keywords
hyp
lys
peptide
tyr
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021514112A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022500437A (ja
JPWO2020052677A5 (https=
JP2022500437A5 (https=
Inventor
インゲマル サミュエルソン,ベンクト
ガオ,ミン
Original Assignee
ジャンイン ユスン ファーマシューティカル カンパニー,リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ジャンイン ユスン ファーマシューティカル カンパニー,リミテッド filed Critical ジャンイン ユスン ファーマシューティカル カンパニー,リミテッド
Publication of JP2022500437A publication Critical patent/JP2022500437A/ja
Publication of JPWO2020052677A5 publication Critical patent/JPWO2020052677A5/ja
Publication of JP2022500437A5 publication Critical patent/JP2022500437A5/ja
Application granted granted Critical
Publication of JP7759693B2 publication Critical patent/JP7759693B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021514112A 2018-09-14 2019-09-14 モンテルカストおよびペプチドの新規接合体 Active JP7759693B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2018/105703 2018-09-14
CN2018105703 2018-09-14
CNPCT/CN2018/119072 2018-12-04
CN2018119072 2018-12-04
PCT/CN2019/105832 WO2020052677A1 (en) 2018-09-14 2019-09-14 New conjugates of montelukast and peptides

Publications (4)

Publication Number Publication Date
JP2022500437A JP2022500437A (ja) 2022-01-04
JPWO2020052677A5 JPWO2020052677A5 (https=) 2022-09-21
JP2022500437A5 JP2022500437A5 (https=) 2022-09-21
JP7759693B2 true JP7759693B2 (ja) 2025-10-24

Family

ID=69777394

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021514112A Active JP7759693B2 (ja) 2018-09-14 2019-09-14 モンテルカストおよびペプチドの新規接合体

Country Status (27)

Country Link
US (2) US11680082B2 (https=)
EP (2) EP4253404A3 (https=)
JP (1) JP7759693B2 (https=)
KR (1) KR102946621B1 (https=)
CN (2) CN111601618A (https=)
AU (1) AU2019338582B2 (https=)
BR (1) BR112021004823A2 (https=)
CA (1) CA3112420A1 (https=)
DK (1) DK3678705T5 (https=)
ES (1) ES2956509T3 (https=)
FI (1) FI3678705T3 (https=)
HR (1) HRP20230946T1 (https=)
HU (1) HUE062848T2 (https=)
IL (1) IL281426A (https=)
LT (1) LT3678705T (https=)
MX (1) MX2021002657A (https=)
MY (1) MY205435A (https=)
PL (1) PL3678705T3 (https=)
PT (1) PT3678705T (https=)
RS (1) RS64436B1 (https=)
SA (1) SA521421448B1 (https=)
SG (1) SG11202102119RA (https=)
SI (1) SI3678705T1 (https=)
SM (1) SMT202300210T1 (https=)
TW (1) TWI875712B (https=)
WO (1) WO2020052677A1 (https=)
ZA (1) ZA202101398B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020000029A (es) * 2017-07-05 2020-08-06 Jiangyin Mucocare Pharmaceutical Co Ltd Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon.
MX2022003057A (es) * 2019-09-14 2022-06-16 Jiangyin Usun Pharmaceutical Co Ltd Nuevos peptidos.
CA3160167A1 (en) * 2019-12-02 2021-06-10 Ming Gu Peptides and their use in the treatment of inflammation
WO2021207606A1 (en) * 2020-04-10 2021-10-14 University Of Georgia Research Foundation, Inc. Methods for treatment of coronavirus infections
US11116737B1 (en) 2020-04-10 2021-09-14 University Of Georgia Research Foundation, Inc. Methods of using probenecid for treatment of coronavirus infections
KR102596264B1 (ko) * 2020-11-30 2023-11-01 주식회사 바이오빛 기능성 펩티드가 결합된 생체적합 폴리펩티드를 포함하는 염증 질환의 억제용 조성물
US20240165247A1 (en) * 2021-03-17 2024-05-23 Jiangyin Usun Pharmaceutical Co., Ltd. New peptide conjugates
WO2022193186A1 (en) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. New diagnostic and therapeutic agents
WO2023225107A1 (en) * 2022-05-17 2023-11-23 Emory University Diroximel fumarate, inhalation administration methods, pharmaceutical uses and compositions
EP4665372A1 (en) * 2023-02-13 2025-12-24 EnliTISA (Shanghai) Pharmaceutical Co., Ltd. New multi-functional oligopeptides
WO2024260465A1 (en) * 2023-06-22 2024-12-26 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. New multi-functional oligopeptides
TW202535906A (zh) * 2023-10-23 2025-09-16 大陸商安利提沙(上海)製藥有限公司 新型短鏈肽及其衍生物
KR20250075990A (ko) * 2023-11-22 2025-05-29 한도숙 상처 치료 또는 피부 주름형성 억제용 조성물
WO2025195444A1 (en) 2024-03-20 2025-09-25 Enlitisa (Shanghai) Pharmaceutical Co., Ltd. New use of peptides derived from vasoactive intestinal peptide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005524677A (ja) 2002-02-22 2005-08-18 ニュー リバー ファーマシューティカルズ インコーポレイテッド 活性物質送達系及び活性物質を保護し投与する方法
JP2013504579A (ja) 2009-09-09 2013-02-07 ファーマイン コーポレーション 治療剤の送達のための陰イオンコア組成物およびその製造ならびに使用方法
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
WO2003020200A2 (en) * 2000-11-16 2003-03-13 New River Pharmaceuticals Inc. A novel pharmaceutical compound and methods of making and using same
PL374646A1 (en) 2002-07-08 2005-10-31 Pliva-Istrazivacki Institutt D.O.O. Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use
US20050107612A1 (en) 2002-12-30 2005-05-19 Dr. Reddy's Laboratories Limited Process for preparation of montelukast and its salts
CA2522007A1 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Methods of preventing or treating respiratory conditions
JP4764818B2 (ja) * 2003-04-11 2011-09-07 メディミューン,エルエルシー 組換えil−9抗体およびその使用
CN101123878A (zh) 2003-07-29 2008-02-13 信号研发控股有限责任公司 氨基酸前药
US8173840B2 (en) 2003-07-29 2012-05-08 Signature R&D Holdings, Llc Compounds with high therapeutic index
ES2337915T3 (es) 2004-10-27 2010-04-30 Glaxosmithkline Istrazivacki Centar Zagreb D.O.O. Conjugados con adtividad antiinflamatoria.
TW200740441A (en) * 2005-06-17 2007-11-01 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
CN102068432A (zh) 2011-01-11 2011-05-25 李仲昆 一种由他定类和白三烯拮抗剂组成的外用复方组合物
WO2012112690A2 (en) * 2011-02-16 2012-08-23 Fabius Biotechnology Targeting of therapeutic drugs and diagnostic agents employing collagen binding domains
CN116898848A (zh) 2012-01-18 2023-10-20 苏州泰飞尔医药有限公司 治疗肺部疾病的高穿透力前药组合物和医药组合物
WO2014164285A2 (en) * 2013-03-13 2014-10-09 Inflammatory Response Research, Inc. Use of levocetirizine and montelukast in the treatment of vasculitis
US20160060328A1 (en) * 2013-10-25 2016-03-03 Lpath, Inc. Compositions and methods for binding cysteinyl leukotrienes (cyslts) for treatment of disease
KR102468519B1 (ko) * 2015-07-20 2022-11-21 장인 벵트 아이. 사무엘손 인스티튜트 오브 라이프 사이언스 컴퍼니 리미티드 피부 염증의 억제에서의 홍합 접착 단백질 제품 및 이의 적용
BR112019024563A2 (pt) 2017-05-24 2020-06-23 Transfert Plus S.E.C. Compostos peptídicos, compostos conjugados e usos dos mesmos para tratar doenças inflamatórias
JP7198785B2 (ja) * 2017-07-05 2023-01-04 ジャンイン ユスン ファーマシューティカル カンパニー,リミテッド ペプチドの抗炎症的使用
MX2020000029A (es) * 2017-07-05 2020-08-06 Jiangyin Mucocare Pharmaceutical Co Ltd Formulaciones topicas que comprenden montelukast y combinaciones con proteinas adhesivas del mejillon.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005524677A (ja) 2002-02-22 2005-08-18 ニュー リバー ファーマシューティカルズ インコーポレイテッド 活性物質送達系及び活性物質を保護し投与する方法
JP2013504579A (ja) 2009-09-09 2013-02-07 ファーマイン コーポレーション 治療剤の送達のための陰イオンコア組成物およびその製造ならびに使用方法
JP2017526728A (ja) 2014-09-15 2017-09-14 インフラマトリー・レスポンス・リサーチ・インコーポレイテッド 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Don A. Cowan,The marine biosphere: a global resource for biotechnology,Trends in Biotechnology,vol.15, no.4,1997年,pp.129-131

Also Published As

Publication number Publication date
FI3678705T3 (fi) 2023-07-04
KR102946621B1 (ko) 2026-04-01
DK3678705T5 (da) 2024-09-16
EP4253404A2 (en) 2023-10-04
KR20210061372A (ko) 2021-05-27
AU2019338582B2 (en) 2026-01-15
US20210309696A1 (en) 2021-10-07
LT3678705T (lt) 2023-08-10
JP2022500437A (ja) 2022-01-04
SMT202300210T1 (it) 2023-09-06
EP4253404A3 (en) 2023-12-13
CA3112420A1 (en) 2020-03-19
IL281426A (en) 2021-04-29
US11680082B2 (en) 2023-06-20
SI3678705T1 (sl) 2023-10-30
EP3678705A4 (en) 2021-06-09
HUE062848T2 (hu) 2023-12-28
TW202023623A (zh) 2020-07-01
SG11202102119RA (en) 2021-04-29
ES2956509T3 (es) 2023-12-22
DK3678705T3 (en) 2023-06-26
RS64436B1 (sr) 2023-09-29
ZA202101398B (en) 2022-09-28
MX2021002657A (es) 2021-07-21
MY205435A (en) 2024-10-21
HRP20230946T1 (hr) 2023-11-24
BR112021004823A2 (pt) 2021-06-08
AU2019338582A1 (en) 2020-11-19
CN116785447A (zh) 2023-09-22
CN116785447B (zh) 2024-11-22
WO2020052677A1 (en) 2020-03-19
EP3678705A1 (en) 2020-07-15
US20230348536A1 (en) 2023-11-02
CN111601618A (zh) 2020-08-28
PT3678705T (pt) 2023-07-19
TWI875712B (zh) 2025-03-11
PL3678705T3 (pl) 2023-10-09
SA521421448B1 (ar) 2024-03-14
EP3678705B1 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
JP7759693B2 (ja) モンテルカストおよびペプチドの新規接合体
JP2026000993A (ja) 新ペプチド
US20240218016A1 (en) Peptides and their use in the treatment of inflammation
US20220105082A1 (en) New formulations containing leukotriene receptor antagonists
RU2838061C9 (ru) Новые конъюгаты монтелукаста и пептидов
RU2838061C2 (ru) Новые конъюгаты монтелукаста и пептидов
HK40101414A (en) Conjugates of montelukast and peptides
US12612430B2 (en) Peptides
MD3678705T2 (ro) Conjugați de montelukast și peptide
HK40033390B (en) Conjugates of montelukast and peptides
HK40033390A (en) Conjugates of montelukast and peptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220912

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220912

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230905

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240304

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241015

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250827

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250909

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251009

R150 Certificate of patent or registration of utility model

Ref document number: 7759693

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150